Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Raxdil is a brand of cefadroxil, a first-generation cephalosporin antibiotic distributed by Rax Health Care. It is indicated for the treatment of various bacterial infections, including urinary tract infections, skin and soft tissue infections, and infections of the pharynx (pharyngitis) and tonsils (tonsillitis). As a beta-lactam antibiotic, cefadroxil exerts its bactericidal effect by binding to and inactivating penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. This inhibition prevents the cross-linking of peptidoglycan chains, which is essential for bacterial cell wall integrity, leading to cell lysis and death. Raxdil is available in multiple liquid formulations, including oral suspensions and drops, to accommodate different patient needs and administration routes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Raxdil.